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Abstract: Agranulocytosis is a rare yet severe idiosyncratic adverse drug reaction to metamizole,
an analgesic widely used in countries such as Switzerland and Germany. Notably, an underlying
mechanism has not yet been fully elucidated and no predictive factors are known to identify
at-risk patients. With the aim to identify genetic susceptibility variants to metamizole-induced
agranulocytosis (MIA) and neutropenia (MIN), we conducted a retrospective multi-center
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collaboration including cases and controls from three European populations. Association analyses
were performed using genome-wide genotyping data from a Swiss cohort (45 cases, 191 controls)
followed by replication in two independent European cohorts (41 cases, 273 controls) and a joint
discovery meta-analysis. No genome-wide significant associations (p < 1 × 10−7) were observed in the
Swiss cohort or in the joint meta-analysis, and no candidate genes suggesting an immune-mediated
mechanism were identified. In the joint meta-analysis of MIA cases across all cohorts, two candidate
loci on chromosome 9 were identified, rs55898176 (OR = 4.01, 95%CI: 2.41–6.68, p = 1.01 × 10−7) and
rs4427239 (OR = 5.47, 95%CI: 2.81–10.65, p = 5.75 × 10−7), of which the latter is located in the SVEP1
gene previously implicated in hematopoiesis. This first genome-wide association study for MIA
identified suggestive associations with biological plausibility that may be used as a stepping-stone
for post-GWAS analyses to gain further insight into the mechanism underlying MIA.
Keywords: drug-induced agranulocytosis; metamizole; dipyrone; genome-wide association
study; pharmacogenetics
1. Introduction
Metamizole, or dipyrone, is an analgesic and antipyretic drug used to manage different types of
pain as well as fever and often serves as an alternative to therapy with conventional non-steroidal
anti-inflammatory drugs (NSAIDs). Despite a well-known favorable gastrointestinal safety profile [1–3],
spontaneous adverse drug reaction (ADR) reports with risk estimates varying between different
countries [4–6] provide accounts of metamizole-induced blood dyscrasias. Specifically, these include
metamizole-induced neutropenia (MIN) and a more severe form, agranulocytosis (MIA) characterized
by a decrease in circulating neutrophil granulocytes below 1.5 × 109 cells/L, and 0.5 × 109 cells/L,
respectively [7,8]. Consequently, the use of metamizole is currently subjected to contrasting regulations
put in place by different government authorities, ranging from market withdrawal to non-prescription
use [4,5,9–12]. To date, the pathogenesis and biologic markers of risk for metamizole-induced
agranulocytosis (MIA) remain poorly understood and there are no effective strategies for prediction
or prevention.
Genome-wide association studies (GWAS) have served as a cost-effective approach to identify
associations of single nucleotide polymorphisms (SNPs) with a variety of human phenotypes ranging
from complex diseases to drug-related outcomes. In particular, previous GWAS have identified
associations of genetic variants with rather large effect sizes for the susceptibility to various rare
and serious adverse drug reactions (ADRs) such as flucloxacillin-induced liver injury, statin-induced
myopathy and carbamazepine-induced skin injury [13,14]. In more recent years, studies of idiosyncratic
drug-induced agranulocytosis identified genes associated with increased risk either in the human
leukocyte antigen (HLA) region or in other regions involved in immune responses for culprit drugs
such as clozapine, carbimazole and sulfasalazine [15–19].
Although the biological significance of many of the reported associations has only partially
been unmasked, these findings would tend to favor the involvement of the immune system in
these adverse drug reactions. Conversely, for metamizole, recent evidence from mechanistic in vitro
studies is not in agreement with an immune-system driven mechanistic hypothesis as it has been
shown that the main metamizole metabolite MAA (N-methyl-4-aminoantipyrine) reacts with the
hemoglobin break down product hemin to produce a reactive intermediate that is cytotoxic for
promyelocytic HL60 cells, but not mature neutrophil granulocytes [20–22]. Given this conflicting
evidence, exploring genetic associations with MIA could be helpful to shed more light on whether to
support or reject either hypothesis.
To identify loci associated with metamizole-induced neutropenia/agranulocytosis, we performed
single-marker tests of association by means of a GWAS using genotype data from the largest MIA/MIN
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cohort to date (86 cases, 464 controls). Genetic variants in 84 candidate genes were analyzed in a Swiss
discovery cohort (45 cases, 191 controls), with replication of findings and a genome-wide meta-analysis
in two independent cohorts genotyped by the European Drug-induced Agranulocytosis Consortium
(EuDAC).
2. Materials and Methods
2.1. Ethical Statement
This study was approved by the local ethics committees “Ethikkommission Nordwest- und
Zentralschweiz” and “Kanton Bern” in Switzerland (EKNZ BASEC 2015–00231, KEK-Nr 2015-00231).
Research was conducted according to the latest update of the Declaration of Helsinki. Collection of
biological materials and clinical information was undertaken with a written informed consent from
all participants. Samples and data of German (EuDAC-DE) and Spanish (EuDAC-ES) patient cohorts
had previously been collected through the European Drug-induced Agranulocytosis Consortium
(EuDAC) with approval by the local ethics committees (22 December 2014, Málaga, Spain; RTF011,
Barcelona, Spain; Charité–Universitätsmedizin Berlin, Germany).
2.2. Study Design and Participants
This retrospective observational case-control study included genotype data from a Swiss discovery
cohort (MIA/MIN-CH) that consisted of a total of 53 cases, 39 tolerant controls and 161 unexposed
controls recruited at the University Hospitals Basel and Bern. MIN and MIA were defined by an absolute
neutrophil count (ANC) below 1.5 × 109 cells/L, and 0.5 × 109 cells/L respectively. Tolerant controls
included in the study had received at least 500 mg metamizole per day for a minimum of twenty-eight
consecutive days, a treatment duration encompassing the latency time observed for a majority of cases
for the occurrence of MIA based on a previous report [6]. Clinical drug tolerability during metamizole
therapy was assessed by the absence of symptoms including fever, sore throat, or mucositis [23].
EDTA blood samples for genetic analyses were collected and coded at the time of recruitment.
Clinical data, including patient characteristics and concomitant drug therapy (such as antibiotics,
analgesics and β-lactam antibiotics) were retrieved from medical charts. A more detailed description
of participants recruited for this study has been previously published [23]. In addition, participants
genotyped as part of a project of the EuDAC were assigned to two independent replication cohorts
based on their recruitment site: Germany (EuDAC-DE) and Spain (EuDAC-ES). Additional description
of these cohorts is available in previous reports [16]. The majority of subjects were of self-reported
European ancestry, which was consistent with multidimensional scaling (MDS) analyses of population
structure using genome-wide genotype data (see further details below).
2.3. Genotype Data and Quality Control
For the samples of the MIA/MIN-CH discovery cohort, genomic DNA from whole blood
or buffy coat was extracted and purified using the QIAamp DNA Blood Maxi or Midi Kits
(Qiagen, Hilden, Germany) according to the manufacturer’s instructions. Eluted DNA was quantified
with the Qubit 4 Fluorometer (ThermoFisher Scientific, Waltham, MA, USA) and quality was
assessed by measuring absorbance at A230, A260 and A280 on a NanoDrop 1000 Spectrophotometer
(ThermoFisher Scientific).
Genotyping in each of the contributing cohorts was conducted independently at different time
points using various high-density SNP arrays (Figure 1). For the MIA/MIN-CH cohort, genotyping was
performed using the Infinium Human CoreExome-24 BeadChip and processed by the iScan System
together with a customized Tecan liquid-handling robot (both Illumina, San Diego, CA, USA) at the
iGE3 Facility (University of Geneva, Geneva, Switzerland). Genotype calls were generated with the
GenomeStudio software (Illumina). For replication and meta-analyses, existing genotype data was
obtained through the EuDAC.
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Figure 1. Study design. Cases and controls were genotyped separately using the indictaed Illumina 
arrays. MIA/MIN‐CH = Swiss cohort, EuDAC‐ES = Spanish cohort, EuDAC‐DE = German cohort, SNP 
= single nucleotide polymorphisms, K = 1000, M = 100,000. 
In all datasets, SNP positions were based on National Center  for Biotechnology  Information 
(NCBI, Bethesda, MD, USA) build 37 (hg19) and alleles were labeled on the positive strand of the 
reference genome. Similar genotyping quality control (QC) procedures [24–28] were used for each 
cohort using PLINK v1.9 [29]. Specifically, individual samples were removed if more than 2% of SNPs 
failed genotyping  (call  rate < 98%), and  individual SNPs were removed  if  they showed a Hardy‐
Weinberg Equilibrium (HWE) p‐value < 0.001 [30–34], a minor allele frequency (MAF) < 1%, if more 
than 2% of samples were flagged as having failed genotype calling for any given SNP (call rate < 98%) 
and if any duplicate or triplicate discordance was detected. 
The rs111876221 polymorphism in the SERINC5 gene was additionally genotyped in the MIA‐
CH  cohort using Polymerase Chain Reaction  (PCR) TaqMan qPCR Master Mix  2× and a  custom 
TaqMan  SNP Genotyping  assay  kit  (cat.  4331349, Assay  ID‐ANZTJD4,  ThermoFisher  Scientific), 
according to the manufacturer’s recommendations. Real‐time PCR reactions were performed using 
10 μL final reaction volumes, consisting of 5 μL 2× master mix, 4.75 μL water, 0.25 μL 40× probe assay 
and  1.0  μL  gDNA.  The  amplification  was  performed  with  the  QuantStudio™  6  Flex  System 
(ThermoFisher Scientific). The PCR program used was as follows: 10 min at 95 °C with at least 40× 
(15 s at 95 °C and 1 min at 60 °C). TaqMan assay results were validated (seven samples homozygous 
for  the  major  allele,  all  samples  with  heterozygous  genotype  and  other  samples  with  an 
undetermined genotype) using Sanger sequencing. Details pertaining to the SNP primer sequences 
utilized for genotype validation can be found in Supplementary Table S1. 
i re 1. Study design. Cases and contr ls were genotyped separately using the
indictaed Illumina arrays. MIA/MIN- H Swiss c rt, EuDAC- S = Spanis cohort,
EuDAC-DE = German cohort, SNP = single nucleotide polymorphisms, K = 1000, M = 100,000.
, ,
. Si ilar genotyping quality control ( ) r ce res [ 28] r
using PLINK v1.9 [29]. Specifically, individu l samples were removed if more than 2% of
SNPs failed ge otyping (call rate < 98%), and individual SNPs were remov d if they showe a
Hardy-Weinberg Equilibrium (HWE) p-value < .001 [30–34], a minor allele frequency (MAF) < 1%,
if more than 2% of samples were flagged as having failed genotype calling for any giv n SNP
(call rate < 98%) nd if any duplicate or triplicate discordance was detected.
rs111876 21 polymorphism in the SERINC5 gene was additionally genotyped in the
MIA-CH cohort using Polymerase Ch in Reaction (PCR) Ta Man qPCR aster Mix 2× and a
custom TaqMan SNP Genotyping assay ki (cat. 4 31349, Assay ID-ANZTJD4, ThermoFisher Scientific),
. l-ti e ti
µ final reaction volumes, con isting of 5 µL 2× master mix, 4.75 µL water, 0.25 µL 40× probe
ssay and 1.0 µL gDNA. The amplification was pe formed with the QuantStudio™ 6 Flex
cientific). The PCR program used was as f llows: 10 min at 95 ◦C wi h t least
40× (15 s at 95 ◦C a d 1 min at 60 ◦C). T qMan a say results were alidated (seven sample
homozygous for th major allele, all samples with heterozy ous genotype and other samples with
) t ils t i i t
l .
Genes 2020, 11, 1275 5 of 21
2.4. Multidimensional Scaling and Identification of Genetic Outliers
Multi-dimensional scaling (MDS) analysis was performed independently for each cohort using
PLINK 1.9 [29]. SNPs that passed quality control were pruned using the linkage disequilibrium (LD)
pruning parameters of r2 < 0.2 over a window size of 50. Genome-wide identity-by-descent (IBD)
given identity-by-state (IBS) information was calculated using all SNPs that remained after pruning.
Five nearest neighbors were identified for each individual based upon the pairwise IBS distance
and the distance to the nth nearest neighbor was converted to a Z score. Fourteen individuals
(nine in MIA/MIN-CH, two in EuDAC-ES and three in EuDAC-DE) with a minimum Z score less than
−2 among the five nearest neighbors were excluded from analysis as population outliers. Furthermore,
three pairs of EuDAC individuals (one in EuDAC-DE and two in EuDAC-ES) showed high levels of
IBD sharing and one individual from each pair was randomly selected to be excluded from subsequent
analyses due to this cryptic relatedness.
2.5. Imputation
Imputation of SNPs was performed by minimac3 [35–37] on the Michigan Imputation Server [38]
using the Haplotype Reference Consortium (HRC 1.1 2016) reference panel [39] on the basis of
pre-imputation SNP-level validated data (https://www.well.ox.ac.uk/~wrayner/tools/) from each
cohort (Supplementary Table S2). HRC-based imputation was performed separately for each cohort,
which increased the genome-wide SNP densities to 39′004′932, 38′994′811 and 39′008′189 SNPs
for MIA/MIN-CH, EuDAC-ES and EuDAC-DE respectively. After performing quality control as
described above, a total of 7′608′978, 7′675′043 and 7′422′709 SNPs were retained for the meta-analysis
performed using a fixed-effects model in the MIA-CH, EuDAC-ES and EuDAC-DE cohorts respectively.
2.6. Candidate Gene and Genome-Wide Association Analyses
All analyses were carried out with PLINK (version 2.0) using logistic regression with the first four
MDS dimensions and sex (only for EuDAC-ES) chosen as covariates. An additive genetic model was
assumed for all variants and the genomic inflation factor was calculated for each analysis to assess
potential confounding effects of population stratification [40,41].
Association analyses were carried out in multiple steps: Initial discovery analyses were
carried out both in the entire MIA/MIN-CH cohort (N = 45 MIA/MIN cases, N = 191
tolerant/unexposed controls) and including only agranulocytosis cases of this cohort (N = 30 MIA cases,
N = 191 tolerant/unexposed controls) focusing first on specific candidate gene sets followed by
genome-wide association analyses. Candidate variants identified in the MIA/MIN-CH cohort were
subsequently investigated for replication in the EuDAC cohorts. In a second discovery analysis,
a genome-wide meta-analysis was carried out including association summary statistics from all three
cohorts (Figure 1). In all analyses, tolerant and unexposed controls were combined as a control group
in the MIA/MIN-CH cohort.
To perform candidate gene analyses, we analyzed different genes following a two-stage approach.
First, eight genes were previously identified by association studies [15,42–47] of agranulocytosis induced
by other drugs (NOX3, SERINC5, NQO2, GSTM1, SLCO1B3, SLCO1B7, TAP2, AGER; Phase I set) were
selected and then 50 additional candidate genes (Phase II set) were included for their hypothesized
relationship to drug-induced agranulocytosis based on their functional annotation potentially related to
the oxidative metabolism of metamizole [48], the anti-oxidant defense [20,22] and the immune system
defense response specific to genes expressed in granulocytes [49]. For each gene, we examined SNPs in
a window of 10kb upstream and downstream of the gene. We used a statistical significance threshold
p-value based on the method of Li et al. [34], which calculates the effective number of independent
tests (Me) and applies a Bonferroni correction based on that number. A list of all genes part of the
Phase II gene set is reported in a separate Supplementary Table S3.
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For all genome-wide analyses, a threshold p-value of 1 × 10−7 was used to declare whether an
association signal was statistically significant at a genome-wide level. This threshold was used based
on an evaluation of empirical replication success of discovery GWAS, demonstrating good replication
success for borderline associations with p < 1 × 10−7 [50]. The SNP association p-values from the three
cohorts were subjected to meta-analysis with METAL using an inverse variance weighted scheme [51].
Identified candidate loci were further investigated for other traits associated with variation in these
regions using publicly available databases of GWAS results (https://genetics.opentargets.org) and for
effects on regulatory motifs or on expression from eQTL studies [52].
3. Results
3.1. Cohort Characteristics
Of the 96 cases of metamizole-induced agranulocytosis identified, ten were excluded
after adjudication: eight cases in MIA/MIN-CH (two because they were identified as suggested
genetic outlier i.e., nearest neighbor analyses suggesting non-European ancestry, two because of
ongoing infectious diseases, four because of immunosuppressive therapy with cytotoxic drugs) and
two cases in EuDAC-ES (because of suggested genetic outlier). No cases were excluded in the
EuDAC-DE cohort.
Of the 479 controls identified, data from fifteen samples were excluded after adjudication:
nine controls in MIA/MIN-CH (one individual was recruited twice as determined by IBD analysis,
seven individuals because they were identified as suggested genetic outlier, and one because of
sample genotype call rate < 50%), two controls in EuDAC-ES (because of cryptic relatedness)
and four controls in EuDAC-DE (three because of suggested genetic outlier and one because of
cryptic relatedness). Demographic characteristics of the tolerant and unexposed controls in the discovery
cohort (MIA/MIN-CH) are presented in Supplementary Table S4. Comparison of demographic and
clinical factors between the three independent cohorts are shown in Table 1. Cases were balanced by sex
and age. Data on sex and age was unavailable for controls in the EuDAC-DE and EuDAC-ES cohorts.
Table 1. Characteristics of cases and controls in the three independent cohorts. Data are N(%) or
median (range). a cases, b controls, * latency missing for 3 MIA cases and 1 MIN case. ANC = lowest
absolute neutrophil count, BMI = body mass index, NA = not applicable/not available.
Cohort
MIA/MIN-CH EuDAC-DE EuDAC-ES
Cases Controls Cases Controls Cases Controls
N = 45 N = 191 N = 12 N = 92 N = 29 N = 181
ANC < 500/uL 30 (67) - 12 - 29 -
Sex, male (%) 13 (42) 17 (45) 4 (33) 41 (44.5) 6 (21) 87 (48)
Age, years (%)
<25 7 (23) 1 (3) 2 (16.6) NA 3 (10.3) NA
25–44 11 (35) 6 (16) 6 (50) NA 6 (21) NA
45–64 10 (32) 15 (39) 2 (16.6) NA 12 (41.4) NA
65–74 3 (10) 9 (24) 2 (16.6) NA 5 (17) NA
>74 - 7 (18) - NA 3 (10.3) NA
BMI, median (range) 24 (19–47) 28 (16–39) NA NA NA NA
Latency time * a/treatment duration b, days 17 (1–204) 25 (1–5297) 33.5 (4–9855) NA 11.5 (1–235) NA
3.2. Association Analyses in the Discovery Cohort (MIA/MIN-CH and MIA-CH)
3.2.1. Candidate Gene Analyses
In the Swiss discovery cohort of 236 individuals, the genomic inflation factor (λ) was λ = 1.00
and no systemic bias was detected in any of the analyses that were conducted. The standard per-SNP
significance threshold for a family-wise error rate (FWER) of α = 0.05 was estimated at 5.4 × 10−4
for the phase I candidate gene analysis and 1.08 × 10−4 for phase II. No statistically significant
SNPs associated with MIA/MIN and MIA, respectively were identified in either phase I or phase II
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when including all 45 MIA and MIN cases (Supplementary Tables S5 and S6) or only the 30 MIA
cases (Supplementary Tables S7 and S8). The top finding in both phase I analyses was a common
intronic variant in the serine incorporator 5 (SERINC5) gene (rs10041917, p = 3.4 × 10−3, OR = 0.44,
95%-CI 0.25–0.76). This signal remained the top finding also in the analysis of the extended number of
candidate genes in phase II. The rs10041917 variant in SERINC5 was in linkage disequilibrium with a
variant (rs111876221) previously reported to be associated with sulfasalazine-induced agranulocytosis
(D’ = 1.0, p = 0.0068) as determined using the LDpair tool in LDlink using 1000 Genomes project data
from European populations (https://ldlink.nci.nih.gov/?tab=ldpair). To evaluate a potential association
with MIN/MIA, rs111876221 was separately genotyped in the entire MIA/MIN-CH cohort as this SNP
was not included on the Infinium array and imputation results were only obtained in a later stage
of the data analysis. Direct genotyping of rs111876221 in the MIA/MIN-CH cohort revealed that the
A allele at that locus, which is linked to the A allele of rs10041917, was found more frequently in
the case group (MAF = 0.055) compared to the controls (MAF = 0.016) indicating the same direction
of effect. This association was shown to be significant with a one-sided Fisher’s exact test p-value of
0.03 (OR = 3.85, 95% 1.12–13.25).
Among the top SNPs from the phase I analysis in agranulocytosis cases only
(Supplementary Table S7), several additional variants were identified as of potential interest.
Specifically, the same missense SNP in the ATP binding cassette subfamily B member (TAP2) gene,
rs2228391 (p = 5.1 × 10−3, OR = 377.7, 95% CI 5.93–24028), as observed here at a higher frequency
in MIA cases was previously associated with susceptibility of a northern Chinese Han population
to antithyroid drug-induced agranulocytosis [53]. In addition, another missense rs4148876 SNP in
TAP2 (p = 6.1 × 10−3, OR = 3.06, 95% CI 1.37–6.83) has been reported to be correlated with gene
expression of the HLA-DOB and TAP2 genes in several tissues including whole blood [54–57], Similarly,
the intergenic variant rs6588432 SNP near the glutathione peroxidase 7 (GPX7) gene, has been reported
to be associated with gene expression of GPX7 and origin recognition complex subunit 1 (ORC1L) in
several tissues including blood [54,57]. Due to their potential functional relevance, these additional
variants were selected to assess replication in the EuDAC cohorts.
3.2.2. Genome-Wide Association Analyses
We performed two genome-wide association analyses of 304,704 genotyped variants, first in the
entire MIA/MIN-CH cohort (N = 45 cases, N = 191 tolerant/unexposed controls) and then including only
MIA cases (N = 30 cases) versus the same 191 controls. None of the SNPs showed an association at the
genome-wide significance level (p < 1× 10−7) in these analyses (Figure 2). In the analysis including both
MIA and MIN cases (Figure 2a), the leading SNP with the best evidence for a suggestive association
was in an intergenic region on chromosome 6 (rs191786, p = 8.6 × 10−6, OR = 0.24, 95% CI 0.13–0.45)
near the TENT5A gene. In the analysis with only MIA cases (Figure 2b), the leading SNP was also in
an intergenic region on chromosome 6 (rs9366076, p = 2.89 × 10−6, OR = 4.81, 95% CI 2.49–9.30).
Interestingly, this lead SNP was previously reported to be associated with gene expression of
the nearby ribonuclease T2 (RNASET2) gene in multiple tissues [55,57,58] and in neutrophils [58].
Supplementary Tables S9 and S10 summarizes the leading associations of the genome-wide analyses.
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Figure 2. Manhattan plot of genome‐wide association analyses in the MIA/MIN‐CH cohort. Results 
from 304,704 genotyped SNPs after quality control are shown, adjusted by multidimensional scaling 
(MDS) dimensions 1‐4: (a) Analysis of all 45 cases (MIA and MIN) versus 191 controls (tolerant and 
unexposed  combined). The  top  SNP was  rs191786,  located  in  an  intergenic  region nearest  to  the 
TENT5A gene on chromosome 6; (b) Analysis of 30 MIA cases versus 191 tolerant/unexposed controls. 
The  top  SNP was  rs9366076,  located  in  an  intergenic  region  nearest  to  the  RNASET2  gene  on 
chromosome 6. The red line shows the threshold for genome‐wide significance of 1 × 10−7. 
Interestingly, this lead SNP was previously reported to be associated with gene expression of 
the nearby ribonuclease T2 (RNASET2) gene  in multiple tissues [55,57,58] and  in neutrophils [58]. 
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Results from 304,704 genotyped SNPs after quality control are shown, adjusted by multidimensional
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3.2.3. Replication in Independent Cohorts
To evaluate potential replication of these candidate associations in indepe dent cohorts,
directly typed and imputed genotype dat from the EuDAC-ES and EuDAC-DE cohorts was used
(Supplementary Table S11). Based on genome-wide association analyses for 1,786,726 genotyped SNPs
in the EuDAC-ES cohort and 650,136 SNPs in the EuDAC-DE cohort, no evidence of systemic bias was
detected in these datasets with genomic inflation factors (λ) of λ = 1.016 and λ = 1.047 in the EuDAC-ES
and EuDAC-DE cohorts, respectively.
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For the candidate SNPs selected from the phase I and phase II candidate gene analyses in the
MIA/MIN-CH and MIA-CH cohort, we did not observe any significant associations with MIA in the
two independent EuDAC cohorts (Supplementary Table S11). Due to reduced imputation accuracy
in the EuDAC-ES (RSQ = 0.74) and EuDAC-DE (RSQ = 0.26) cohorts, replication of the rs111876221
variant previously associated with sulfasalazine-induced agranulocytosis could not be reliably assessed
in those cohorts. Specifically, the reduced genotype imputation accuracy for this relatively uncommon
SNP was illustrated in the MIA/MIN-CH cohort where the genotype was not correctly imputed for
two out of eleven heterozygous minor allele carriers when compared to direct genotyping, in spite of
an imputation RSQ of 0.91.
Associations of the leading SNPs from both genome-wide analyses in the MIA/MIN-CH and
MIA-CH discovery cohort (Supplementary Tables S9 and S10), rs191786 and rs9366076 near RNASET2,
previously reported as an eQTL of this gene, could not be replicated in the two independent European
cohorts (Supplementary Table S11).
3.3. GWAS Meta-Analysis across Independent Cohorts
For the meta-analyses, genome-wide association results from all three cohorts based on imputed
genotype data were used. Also, in the meta-analysis, two analyses were conducted, first including
MIN cases in the MIA/MIN-CH cohort and a second analysis only considering MIA cases. Manhattan
plots of the results of both meta-analyses are shown in Figure 3. The first meta-analysis performed in
all 86 cases and 464 controls across all three cohorts revealed that a leading SNP with the best evidence
for association in an intronic region of the transforming growth factor β receptor 3 (TGFBR3) gene
on chromosome 1 (rs11583606, p = 1.72 × 10−7, OR = 7.95% CI 3.37–14.5) (Supplementary Figures S1
and S2A). The second strongest independent signal was positioned in an intronic region in the protein
tyrosine phosphatase receptor type O (PTPRO) gene on chromosome 12 (rs112917452, p = 9.92 × 10−7,
OR = 7.3, 95% CI 3.29–16.20) (Supplementary Figures S2B and S3). No association reached statistical
significance at the genome-wide level (Table 2).
The second meta-analysis (Table 3) performed in the 71 MIA cases and 464 controls revealed a
leading SNP with the best evidence for association in an intergenic region on chromosome 9 (rs55898176,
p = 1.01 × 10−7, OR = 4.01, 95% CI 2.41–6.68) (Supplementary Figure S4A), only marginally not meeting
the genome-wide significance threshold. This SNP was identified to be located near a long non-coding
RNA with CAAP1 as the closest coding gene at a distance of 177 kilobases to the canonical Transcript
Start Site (TSS) of the gene (Figure 4).
The second strongest independent signal was positioned in an intronic region in the Sushi
von Willebrand Factor Type A, EGF and Pentraxin Domain Containing 1 (SVEP1) gene, also on
chromosome 9 (rs4427239, p = 5.75 × 10−7, OR = 5.47, 95% CI 2.81–10.65) (Supplementary Figure S4B).
Several other genes located in proximity of SVEP1 include the thioredoxin (TXN) gene, involved in
the cellular antioxidant defense (Figure 4). An evaluation of the frequencies of the associated alleles
for the lead signals from both meta-analyses in the MIN vs. MIA cases of the MIA/MIN-CH cohort is
shown in Supplementary Tables S5 and S6, respectively. Interestingly, the observed allele frequencies
of the leading SNPs show that the risk allele distributions of rs11583606 and rs112917452 were
higher in the MIN cases than in the MIA cases (Supplementary Figure S5). In contrast, the risk
allele distribution of rs55898176 and rs4427239 were higher in the MIA cases than in the MIN cases
(Supplementary Figure S6). Post stage GWAS analysis of these candidate loci using HaploReg [52] and
GTEx [59] did not indicate any potential regulatory effects associated with the top SNPs across the
available gene expression quantitative trait loci (eQTL) datasets. Furthermore, no GWAS lead variants
were found to be linked to any of the candidate loci. However, several hematological measurement
traits such as hemoglobin concentration, autoimmune hemolytic anemias and monocyte count reported
by previous studies were found to be associated (p < 0.05) with the rs112917452, rs55898176 and
rs4427239 variants in the UK Biobank and GWAS catalog summary statistics repository respectively.
Also, several association studies [60] reported associations between lead variants in the SVEP1 gene
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and hematological measurements obtained from blood plasma including neutrophil percentage of
granulocytes (p = 4.5 × 10−14), white blood cell count (p = 2.0 × 10−15), platelet count (p = 2.2 × 10−11)
and eosinophil percentage of granulocytes (p = 9.1 × 10−17).
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Table 2. Top associations of the GWAS meta-analysis with MIA/MIN in all cases versus controls in the three independent European cohorts. Top GWAS
meta-analysis results based on approximately 7 million SNPs after imputation in 83 MIA/MIN cases vs. all 464 controls (tolerant and unexposed). All results were
adjusted for four genetic multidimensional scaling (MDS) components and sex (only for EuDAC-ES). Chromosomal location is according to the Genome Reference
Consortium human assembly GRCh37. CHR = chromosome, SNP = single nucleotide polymorphism, BP = base pair, MAF = minor allele frequency, OR [95%] = odds
ratio with 95% confidence interval, HetISq = I2 statistic which measures heterogeneity on a scale of 0–100%.
CHR SNP Alleles (Minor/Major) BP
MAF Cases
MIA/MIN-CH| EuDAC-ES|
EuDAC-DE
MAF Controls
MIA/MIN-CH| EuDAC-ES|
EuDAC-DE
OR [95%] p-Value Gene Region HetISq
1 rs11583606 T/C 92349247 0.10| 014| 0.083 0.023| 0.025| 0.027 7.0 [3.37–14.5] 1.72 × 10−7 TGFBR3 0
1 rs149072800 C/T 92445720 0.089| 0.12| 0.083 0.020| 0.019| 0.022 7.81 [3.57–17.1] 2.66 × 10−7 BRDT 0
1 rs146378328 G/A 92528047 0.089| 0.10| 0.083 0.018| 0.019| 0.021 8.31 [3.69–18.7] 2.93 × 10−7 EPHX4 0
1 rs75499485 G/A 92486274 0.089| 0.10| 0.083 0.020| 0.019| 0.021 7.96 [3.56–17.8] 4.23 × 10−7 EPHX4 0
12 rs112917452 C/A 15638858 0.067| 0.15| 0.042 0.016| 0.027| 0.016 7.30 [3.29–16.20] 9.92 × 10−7 PTPRO 0
12 rs118135416 A/G 15638914 0.067| 0.15| 0.042 0.016| 0.027| 0.016 7.30 [3.29–16.20] 9.92 × 10−7 PTPRO 0
12 rs7135120 T/C 15626920 0.067| 0.15| 0.042 0.016| 0.027| 0.016 7.30 [3.29–16.20] 9.92 × 10−7 PTPRO 0
12 rs143843248 T/C 15633812 0.067| 0.15| 0.041 0.016| 0.027| 0.016 7.30 [3.29–16.20] 9.92 × 10−7 PTPRO 0
13 rs73163933 A/G 33968020 0.12| 0.086| 0.21 0.036| 0.027| 0.054 5.36 [2.73–10.5] 1.01 × 10−6 STARD13 0
1 rs78201766 G/A 92379078 0.10| 0.14| 0.083 0.026| 0.030| 0.027 5.65 [2.81–11.34] 1.12 × 10−6 TGFBR3 0
Table 3. Top associations of the GWAS meta-analysis in MIA cases versus controls in the three independent European cohorts. Top GWAS meta-analysis results
based on approximately 7 million SNPs after imputation in 71 MIA cases vs. all 464 controls (tolerant and unexposed). All results were adjusted for four genetic
multidimensional scaling (MDS) components and sex (only for EuDAC-ES). Chromosomal location is according to the Genome Reference Consortium human assembly
GRCh37. CHR = chromosome, SNP = single nucleotide polymorphism, BP = base pair, MAF = minor allele frequency, OR [95%] = odds ratio with 95% confidence
interval, HetISq = I2 statistic which measures heterogeneity on scale of 0–100%.
CHR SNP Alleles (Minor/Major) BP
MAF Cases
MIA/MIN-CH| EuDAC-ES|
EuDAC-DE
MAF Controls
MIA/MIN-CH| EuDAC-ES|
EuDAC-DE
OR [95%] p-Value Gene Region HetISq
9 rs55898176 T/C 26715294 0.27| 0.24| 0.25 0.065| 0.12| 0.081 4.01 [2.41–6.68] 1.01 × 10−7 - 21.7
9 rs112223975 C/G 26715828 0.27| 0.24| 0.25 0.065| 0.12| 0.081 3.89 [2.34–6.48] 1.50 × 10−7 - 28.6
9 rs11790418 G/A 26713012 0.27| 0.24| 0.25 0.065| 0.12| 0.098 3.81 [2.29–6.35] 2.54 × 10−7 - 29.3
9 rs1434481 G/C 26711134 0.27| 0.24| 0.25 0.065| 0.11| 0.098 3.81 [2.29–6.35] 2.54 × 10−7 - 29.3
9 rs28475568 G/C 26709933 0.27| 0.24| 0.25 0.065| 0.11| 0.098 3.81 [2.29–6.35] 2.54 × 10−7 - 29.3
9 rs28649995 A/G 26709912 0.27| 0.24| 0.25 0.065| 0.11| 0.098 3.81 [2.29–6.35] 2.54 × 10−7 - 14.6
9 rs56285046 A/G 26714950 0.28| 0.24| 0.25 0.073| 0.12| 0.092 3.70 [2.27–6.05] 3.25 × 10−7 - 0
9 rs77949268 A/G 26738366 0.27| 0.26| 0.25 0.078| 0.12| 0.10 3.59 [2.20–5.87] 3.74 × 10−7 - 0
9 rs4427239 A/G 113270601 0.16| 0.15| 0.041 0.029| 0.041| 0.016 5.47 [2.81–10.65] 5.75 × 10−7 SVEP1 0
9 rs10759436 C/T 113268650 0.15| 0.15| 0.041 0.029| 0.041| 0.016 5.81 [2.92–11.54] 8.13 × 10−7 SVEP1 0
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4. Discussion
We performed candidate gene-based and genome-wide association analyses for
metamizole-induced agranulocytosis in three datasets totaling 86 MIN/MIA cases and 464 controls.
To our knowledge, this is the first study to investigate genetic associations with MIA at a genome-wide
level in the largest patient cohort available to date. In contrast to previous GWAS for agranulocytosis
related to other pharmaceutical agents, we did not identify any genome-wide significant genetic
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associations that would implicate an immune-mediated mechanism for MIA. However, we report
suggestive evidence for an association of two loci on chromosome 9, one of which implicates anti-oxidant
components as well as hematopoiesis, that could serve as plausible candidates for studies to come.
Overall, the genetic susceptibility to rare yet potentially lethal adverse drug reactions, ranging from
skin and liver injury to agranulocytosis, has been repeatedly shown to be specific to each offending
drug [61–65]. Nevertheless, common underlying T cell-mediated mechanisms have been identified
for some drug-induced serious skin reactions and drug-induced liver injury. Similarly, the strongest
pharmacogenetic associations pertaining to drug-induced agranulocytosis up to date mostly involved
immune-related genes such as specific HLA alleles [15–17,44–46,66,67], even though these findings
have yet to be corroborated by mechanistic studies. Here, on the other hand, in line with a previous
association study focused on classical HLA genes in the same cohort [68], none of the candidate loci
identified as leading markers in our genome-wide meta-analysis involved genes that would support
an immune-mediated mechanism underlying MIA. These findings thus suggest that the underlying
mechanism for MIA may differ from other agranulocytosis-inducing drugs. Such a lack of evidence for
an immune-mediated mechanism underlying MIA is concordant with recent in vitro studies suggesting
that the cytotoxicity in immature myeloid cells stems from a reactive electrophilic intermediate formed
from the main metabolite of metamizole, MAA and hemin [20–22]. Genetic variation in enzymes
involved in the heme degradation and antioxidant defense pathways could thus impact an individual’s
susceptibility to develop MAA-associated myelotoxicity.
In this context, the suggestive association of the SNP rs4427239 (chr9p13) in the analysis of only
MIA cases vs. tolerant/population controls is notable due to the reported associations of variants at this
locus with hematopoietic traits and the role of its nearby gene TXN, encoding for thioredoxin (TXN),
in redox control [69–75]. As part of the thioredoxin system, TXN is an antioxidant enzyme found in a
variety of cells including granulocytes [76,77], and is involved in the defense against oxidative stress
by controlling cellular free radicals and reactive oxygen species [78–81]. Functional investigations of
TXN in vitro cell culture models, in particular involving granulocyte precursor cells may thus be of
interest [20,22]. While mRNA expression of SVEP1, the gene in which the lead SNP rs4427239 is located,
was not detected in any immune cells, it was reported to be overexpressed in a hematopoiesis-supporting
splenic stromal cell line [82]. Furthermore, its encoding protein SVEP1 was identified as a ligand of
integrin α 9 β 1 (ITGA9) [83], which is involved in signal transduction in hematopoietic stem cells [84],
and for which an important role has been suggested for granulopoiesis [85]. Given these findings,
SVEP1 also represents an interesting starting point for experimental investigations aiming to clarify
the impact of metamizole and its metabolites on cell adhesion between granulocyte precursors and
stromal cells during maturation.
While the signal related to rs4427239 thus includes two nearby genes with biological plausibility,
the strongest association signal we observed in the meta-analysis including only MIA cases was
the intergenic variant rs55898176 (chr9p13) located near an uncharacterized long non-coding
RNA (LOC105376000). The nearest coding gene to this variant is CAAP1, which encodes conserved
anti-apoptotic proteins that modulate the mitochondrial apoptosis pathway [86]. The possible biological
implications of this association with respect to MIA thus still remains to be elucidated.
Interestingly, the frequencies of both of the above-mentioned lead SNPs, rs4427239 and rs55898176,
were substantially lower in the Swiss MIN cases compared to MIA cases and similar to the frequencies
observed in controls (Supplementary Table S6). The allele frequencies of these SNPs in the MIN
cases thus did not follow an intermediate distribution between the frequencies in the MIA cases
and the controls, as has been observed for genetic associations with other adverse drug reactions
for cases with intermediate severity [87]. If these signals indeed represent true causal associations,
a potential underlying mechanism involving the intergenic locus on chromosome 9, or the SVEP1 locus
in agranulocytosis may not apply to metamizole-induced neutropenia.
Conversely, we observed that the frequencies of the risk alleles for the rs11583606 and rs112917452
SNPs identified as leading markers the meta-analysis of all cases versus controls were substantially
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higher in the Swiss MIN cases compared to the Swiss MIA cases (Supplementary Figure S5).
These signals thus appear to be driven primarily by the MIN cases in the Swiss cohort. The leading
loci from this meta-analysis, TGFBR3 and PTPRO thus showed less consistent effects among the MIA
cases across the three cohorts and as a consequence may not represent the most promising signals
for further investigation. Similarly, both candidate gene analyses (phase I and phase II) revealed
leading markers in the Swiss cohort positioned in intronic regions of the same gene, SERINC5, a gene
coding for transmembrane proteins reducing Human Immunodeficiency Virus (HIV-1) infectivity [88].
In this gene, a genome-wide significant intronic SNP rs111876221 was previously reported to be
associated with sulfasalazine-induced agranulocytosis [15]. However, given that the associations in
this gene were not replicated in the Spanish or German cohorts and the lack of obvious functional
implications of the SERINC5 gene as it relates to MIA, we do not consider this signal as a strong
candidate for further investigation.
None of the identified lead SNPs were located in protein-coding regions or were found to be
eQTLs in previous studies including the 48 human tissues analyzed in the eQTL analysis of the
Genotype-Tissue Expression (GTEx) project [59]. Importantly, however, it should be considered that
the biological interpretation of the candidate loci potentially associated with MIA is hampered by the
scarcity of functional data on the impact of genetic variation on gene expression specifically in bone
marrow or in granulocyte precursors, where cytotoxic effects of metamizole may take place [20,22].
As a consequence, potential regulatory effects of these candidate SNPs at the level of the bone marrow
and specifically during granulocyte maturation cannot be excluded. With the increasing availability
of single-cell RNA sequencing studies providing data at the level of individual cell types or cell
differentiation stages [89–91], additional functional annotation of the identified candidate loci may be
an option in the future.
Main strengths of this study are the fairly homogenous discovery cohort and the possibility of
replication in a second and third cohort. Although the case-control cohorts originated from three
different European countries, by limiting our analyses to individuals of European ancestry using
genetic information and adjusting for residual population structure, the likelihood of false positive
associations due to population stratification was reduced. Also, by adhering to the case definition
criteria of the EuDAC studies for the selection of individuals of the MIA-CH cohort, the three cohorts
were similar in their definition of the ADR phenotype, which provided the advantage of increased
power for the genome-wide meta-analysis.
Although this study has several strengths, it should also be interpreted in the context of
several limitations. First, with the limited sample size, our study was not powered to detect
associations with smaller effect size for uncommon variants. Despite the assembly of large patient
cohorts by large international consortia, studies on rare idiosyncratic adverse drug reactions with
incidences of 1 in 10,000 patients or less, finding it difficult to recruit large enough numbers of cases
and tolerant comparison controls, have been faced with the reality of possibly being underpowered
and to date have commonly included less than hundred cases [92]. Nevertheless, several of these
studies have successfully identified associations due to large effect sizes being commonly observed for
adverse drug reactions compared to genetic associations with common diseases [87,92–95]. To try to
attenuate this limitation, recruitment of more cases and tolerant controls would have been a wishful
but very challenging endeavor given the rarity of MIA. Second, another limitation lies in the use of
population controls instead of drug-tolerant controls. However, the use of population controls instead
of tolerant controls in genetic association studies is suitable for rare ADRs (incidence < 1%) as is the
case for MIA [96]. Third, any residual selection bias stemming from the different recruitment channels
for cases and controls cannot be fully ruled out, even though no systematic genetic differences between
cases and controls were identified by MDS. Finally, considering the lack of statistically significant
associations and the lack of an additional independent replication cohort to further investigate the lead
signals from the genome-wide meta-analysis, it is possible that some of the identified candidate loci,
or possibly even all, represent false positive associations, despite their consistent effects observed in
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the three investigated cohorts. Similarly, genetic variation associated with MIA should be explored in
other populations as well, as the frequency of the identified variants and their clinical impact could
vary between different ethnicities.
5. Conclusions
In this study, we associated genotyped and imputed markers with MIA in three independent
cohorts of European individuals. Taken together, although our findings do not have immediate
clinical utility, they point towards novel candidate genes with a possible role in the mechanism of
MIA in individuals of European ancestry. Interestingly, our findings do not implicate biological
pathways that have been previously identified in association studies for other causal drugs of
agranulocytosis studied in populations of the same ethnicity, for which current evidence is consistent
with an immune-mediated mechanism. Although further studies are warranted to follow up on these
suggestive candidate genes and pathways, our findings are a stepping-stone in the ongoing endeavor
of better understanding the genetic background behind MIA and its underlying causal mechanisms.
Ultimately, this could pave the way to a better screening or treatment for a safer use of metamizole.
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